Rare pituitary diseases in dogs and cats and their human companions

Abstract

The pituitary gland, though small in size, has been recognized for its essential functions since the early 20th century. Dogs played a pivotal role in understanding its endocrine function, and the history of hypophysectomy in humans and dogs is strongly interrelated. While pituitary diseases are rare in humans, they are more prevalent in dogs and cats, with neoplasia representing the most common pathology. These tumors can lead to endocrine disorders such as Cushing’s disease and acromegaly across species. The classification of diverse pituitary adenomas in humans, has prompted their investigation in veterinary patients and the advances in surgical and medical management of pituitary disease exemplify translational medicine. Techniques developed for humans, first evaluated in experimental dogs and subsequently translated into veterinary clinical practice. In the search for novel medical treatment strategies against pituitary diseases in humans, animal studies investigating the feasibility and safety of orphan drugs in large animal models like dogs and cats with spontaneous disease offer valuable information for the initiation of clinical trials in humans. While the incidence of particular pathologies differs between species, there is a common goal for all patients: refining treatment and improving outcomes. This review discusses current status and developments in treatment options for pituitary tumors in companion animals, and takes a look over the shoulder of our human counterparts to see which current, novel and future practices may be promising for our veterinary patients, and investigate how trials with orphan drugs against pituitary disease in veterinary patients can favor human clinical trials.

Keywords

Hypophysis / Cushing’s disease / hypercortisolism / acromegaly / hypersomatotropism / hypophysectomy / pituitary surgery / non-functional pituitary adenoma

References

[1] Galac S,F . Canine endocrinology. In: CH 23: hypothalamus and pituitary gland: anatomy and physiology. Edra Publishing US LLC, 2024; pp. 107-10.

[2] Rijnberk A. Chapter 2: Hypothalamus-pituitary system. In: Clinical endocrinolongy of dogs and cats, an illustrated text. Schlütersche, 2010; pp. 13-54.

[3] Cosio C,Garatti M.Prolactinoma in a Dog.Vet Pathol2017;54:972-6

[4] Sanders K,Meij B.Pituitary tumour types in dogs and cats.Vet J2021;270:105623

[5] Del Magno S,Grinwis GC.Sequential treatment of a large pituitary corticotroph neoplasm and associated neurological signs in a dog.J Am Anim Hosp Assoc2019;55:e552-02

[6] Steele MME,Scudder C.Transsphenoidal hypophysectomy for the treatment of hypersomatotropism secondary to a pituitary somatotroph adenoma in a dog.J Vet Intern Med2024;38:351-7 PMCID:PMC10800194

[7] Blokland-Post K,Tellegen A.Transsphenoidal hypophysectomy as a treatment for Rathke's cleft cyst in a dog.Vet Record Case Rep2022;10:e427

[8] Lehner L,Jakab C,Czeibert K.A recurrent suprapituitary ependymal cyst managed by endoscopy-assisted transsphenoidal surgery in a canine: a case report.Front Vet Sci2019;6:112 PMCID:PMC6476904

[9] Hyde BR,Chen AV.Clinical characteristics and outcome in 15 dogs treated with transsphenoidal hypophysectomy for nonfunctional sellar masses.Vet Surg2022;52:69-80 PMCID:PMC10100401

[10] Martin L,Chen-Allen A,Carrera-Justiz S.Clinical characteristics and outcome in dogs treated with transsphenoidal hypophysectomy for non-functional sellar masses.J Vet Intern Med2016;30:1941

[11] Owen T,Martin L. Why, when, how and post-operative care of dogs undergoing transphenoidal hypophysectomy for large sellar masses. J Vet Intern Med 2016;30:1939. Available from: https://academic.oup.com/jvim/article/30/6/1929/8449772?login=false [Last accessed on 2 Jun 2026]

[12] Owen TJ,Chen AV.Transsphenoidal surgery for pituitary tumors and other sellar masses.Vet Clin N Am Anim Pract2018;48:129-51

[13] Corsello A,Pani F.Dandy: his contributions to pituitary surgery in the context of the overall Johns Hopkins Hospital experience.Pituitary2017;20:683-91 PMCID:PMC5893136

[14] Meij B,Gerritsen R,Ijzer J.Lymphocytic hypophysitis in a dog with diabetes insipidus.J Comp Pathol2012;147:503-7

[15] Rzechorzek NM,Stalin C.Restored vision in a young dog following corticosteroid treatment of presumptive hypophysitis.BMC Vet Res2017;13:63 PMCID:PMC5330113

[16] Bertolini G,Caldin M.Pituitary apoplexy-like disease in 4 dogs.J Vet Intern Med2007;21:1251

[17] Tanaka S,Oishi M,Namiki R.Adrenocorticotropic hormone-producing pituitary adenoma with pituitary apoplexy treated by surgical decompression: a case report.BMC Vet Res2022;18:397 PMCID:PMC9652851

[18] Galli G,Dalla Serra G.Suspected pituitary apoplexy: clinical presentation, diagnostic imaging findings and outcome in 19 dogs.Vet Sci2022;9:191 PMCID:PMC9026492

[19] Woelfel CW,Nolan MW.Presumed pituitary apoplexy in 26 dogs: clinical findings, treatments, and outcomes.J Vet Intern Med2023;37:1119-28 PMCID:PMC10229324

[20] Barnhart KF,Storts RW.Symptomatic granular cell tumor involving the pituitary gland in a dog: a case report and review of the literature.Vet Pathol2001;38:332-6

[21] Ishino H,Teshima T,Sakonju I.Hyperadrenocorticism caused by a pituitary ganglioglioma in a dog.Vet Pathol2019;56:609-13

[22] Polledo L,Graham P,Baiker K.Pathological findings in the pituitary glands of dogs and cats.Vet Pathol2018;55:880-8

[23] Miller MA,Scott-Moncrieff JC.Histopathologic findings in canine pituitary glands.Vet Pathol2018;55:871-9

[24] Snyder J,Skorupski K,Van Winkle T.Secondary intracranial neoplasia in the dog: 177 cases (1986-2003).J Vet Intern Med2008;22:172-7

[25] Gutierrez-Quintana R,Dobromylskyj M,Ortega M.Pituitary metastasis of pancreatic origin in a dog presenting with acute-onset blindness.J Am Anim Hosp Assoc2013;49:403-6

[26] Tamura S,Suzuoka N,Hasegawa T.Multiple metastases of thyroid cancer in the cranium and pituitary gland in two dogs.J Small Anim Pract2006;48:237-9

[27] Menchetti M,Galli G.Neurological abnormalities in 97 dogs with detectable pituitary masses.Vet Q2019;39:57-64 PMCID:PMC6831018

[28] Zou D,Gao R.Long-term pituitary function following transsphenoidal surgery for non-functional pituitary neuroendocrine tumor with apoplexy: a single-center retrospective analysis.Sci Rep2025;15:19226 PMCID:PMC12127470

[29] Miller MA,Donovan TA.Feline pituitary adenomas: correlation of histologic and immunohistochemical characteristics with clinical findings and case outcome.Vet Pathol2020;58:266-75 PMCID:PMC10722206

[30] Wang MTM,Danesh-Meyer HV.Neuro-ophthalmic evaluation and management of pituitary disease.Eye2024;38:2279-88 PMCID:PMC11306754

[31] Shah A.Diaphragma sellae: anatomical and surgical implication in surgery for pituitary adenomas - Highlighting contributions by Goel.J Craniovertebr Junction Spine2018;9:135 PMCID:PMC6187896

[32] Meij BP.Transsphenoidal surgery for pituitary tumors.Vet Clin N Am Anim Pract2025;55:95-118

[33] Teshima T,Shigihara K.Coexistence of corticotroph adenoma and thyrotroph hyperplasia in a dog.J Vet Med Sci2009;71:93-8

[34] Lillehei KO,Barkhoudarian G,Germano IM.Congress of neurological surgeons systematic review and evidence-based guidelines for the role of surgery for patients with functioning pituitary adenomas.Neurosurgery2025;97:24-35

[35] Makarenko S,Karsy M,Couldwell WT.Outcomes and surgical nuances in management of giant pituitary adenomas: a review of 108 cases in the endoscopic era.J Neurosurg2022;137:635-46

[36] Khan DZ,Baldeweg SE,Stoyanov D.Current and future advances in surgical therapy for pituitary adenoma.Endocr Rev2023;44:947-59 PMCID:PMC10502574

[37] Jho H.Endoscopic endonasal transsphenoidal surgery: experience with 50 patients.J Neurosurg1997;87:44-51

[38] Micko A,Brunswick A.Treatment strategies for giant pituitary adenomas in the era of endoscopic transsphenoidal surgery: a multicenter series.J Neurosurg2022;136:776-85

[39] Mortini P,Barzaghi LR.Pituitary surgery.La Presse Med2021;50:104079

[40] Nieman LK,Findling JW.Treatment of cushing's syndrome: an endocrine society clinical practice guideline.J Clin Endocrinol Metab2015;100:2807-31 PMCID:PMC4525003

[41] Puig-Domingo M,Picó A.Pasireotide in the personalized treatment of acromegaly.Front Endocrinol2021;12:648411 PMCID:PMC8008639

[42] Riley G,Klein M.Prognostic indicators in pituitary adenoma surgery: a comprehensive analysis of surgical outcomes and complications.Front Endocrinol2024;14:1327404 PMCID:PMC10808875

[43] Simeoli C,Tortora F.The treatment with pasireotide in Cushing’s disease: effects of long-term treatment on tumor mass in the experience of a single center.Endocrine2015;50:725-40

[44] Starke RM,Vance ML.Radiation therapy and stereotactic radiosurgery for the treatment of Cushing's disease: an evidence-based review.Curr Opin Endocrinol Diabetes Obes2010;17:356-64

[45] Tabaee A,Barrón Y.Endoscopic pituitary surgery: a systematic review and meta-analysis: Clinical article.J Neurosurg2009;111:545-54

[46] Tang OY,Eloy JA.Giant pituitary adenoma - special considerations.Otolaryngol Clin North Am2022;55:351-79

[47] Wattson DA,Spiegel DY.Outcomes of proton therapy for patients with functional pituitary adenomas.Int J Radiat Oncol Biol Phys2014;90:532-9

[48] Fleseriu M,Bancos I.Consensus on diagnosis and management of Cushing’s disease: a guideline update.Lancet Diabetes Endocrinol2021;9:847-75. PMCID:PMC8743006

[49] Meij BP.Hypophysectomy as a treatment for canine and feline cushing's disease.Vet Clin N Am Anim Pract2001;31:1015-41

[50] Sanders K,Galac S.Treating canine Cushing’s syndrome: current options and future prospects.Vet J2018;241:42-51

[51] Brand A,Tas KT.Long-term outcomes of modern radiation therapy for pituitary adenoma - different techniques: single institute experience.J Neurooncol2025;175:1039-50 PMCID:PMC12511260

[52] Maartens NF.The history of the treatment of pituitary adenomas.Endocrine2005;28:009-26

[53] Cucu AI,Perciaccante A,Bianucci R.The evolution of pituitary gland surgery from the ancients to the millennials.World Neurosurg2023;180:52-65

[54] Horsley V.Abstracts of the brown lectures, delivered at the University of London. Lecture III: functional nervous disorders due to loss of thyroid gland and pituitary body.Lancet1886;3-5

[55] Horsley V.Address in surgery: on the technique of operations on the central nervous system.BMJ1906;2:411-23

[56] Caton R.Notes of a case of acromegaly treated by operation.Br Med J1893;2:1421-3 PMCID:PMC2422752

[57] Cushing H. The pituitary body and its disorders; clinical states produced by disorders of the hypophysis cerebri. An amplification of the Harvey lecture for December, 1910. Available from: https://archive.org/details/pituitarybodyits00cushuoft/page/n9/mode/2up [Last accessed on 12 Jun 2026]

[58] Cushing H.Partial hypophysectomy for acromegaly. With remarks on the function of the hypophysis.Ann Surg1909;50:1002-17 PMCID:PMC1407483

[59] Cushing H.Studies in intracranial physiology & surgery. The Cameron Prize Lectures. Oxford University Press; 1926, pp. 52-103.

[60] Bell WB.Experimental operations on the pituitary.Q J Exp Physiol1917;11:77-126

[61] Artico M,Fraioli B.The contribution of davide giordano (1864-1954) to pituitary surgery: the transglabellar-nasal approach.Neurosurgery1998;42:909-11

[62] Cope VZ.The pituitary fossa, and the methods of surgical approach thereto.Br J Surg1916;4:107-44

[63] Hardy J.Transsphenoidal hypophysectomy.J Neurosurg1971;34:582-94

[64] Macfarlane J,Senanayake R.Advances in the imaging of pituitary tumors.Endocrinol Metab Clin North Am2020;49:357-73

[65] Creemers SG,Lamberts SW.Cushing’s syndrome: an update on current pharmacotherapy and future directions.Expert Opin Pharmacother2015;16:1829-44

[66] De Nijs L,Maiter D.Surgical treatment of cushing’s disease: the lessons learned. In: Di Rocco C, editors. Advances and technical standards in neurosurgery. Cham: Springer Nature Switzerland; 2025. pp. 47-73.

[67] Esposito D,Ragnarsson O,Skoglund T.Non-functioning pituitary adenomas: indications for pituitary surgery and post-surgical management.Pituitary2019;22:422-34 PMCID:PMC6647426

[68] Liu JK,Weiss MH,Couldwell WT.The history and evolution of transsphenoidal surgery.J Neurosurg2001;95:1083-96

[69] Lubberink AA.Diagnosis and treatment of canine cushing’s syndrome.Tijdschr Diergeneeskd1989;114:37S-9

[70] Meij BP,Ingh TSVD,Verlaat JWV.Transsphenoidal hypophysectomy in beagle dogs: evaluation of a microsurgical technique.Vet Surg2008;26:295-309

[71] Meij BP,Van Den Ingh TS.Transsphenoidal hypophysectomy for treatment of pituitary-dependent hyperadrenocorticism in 7 cats.Vet Surg2004;30:72-86

[72] Meij BP,Grinwis G,Kooistra HS.Successful treatment of acromegaly in a diabetic cat with transsphenoidal hypophysectomy.J Feline Med Surg2010;12:406-10 PMCID:PMC11318759

[73] Meij B,Van Den Ingh T.Somatotroph and corticotroph pituitary adenoma (double adenoma) in a cat with diabetes mellitus and hyperadrenocorticism.J Comp Pathol2004;130:209-15

[74] Meij BP,Van Den Ingh TSGAM,Rijnberk A.Melanotroph pituitary adenoma in a cat with diabetes mellitus.Vet Pathol2005;42:92-7

[75] Rivenburg R,Martin LG.Pituitary surgery: changing the paradigm in veterinary medicine in the United States.J Am Anim Hosp Assoc2021;57:73-80

[76] Cappabianca P,De Divitiis O,Esposito F.Endoscopic pituitary surgery.Pituitary2008;11:385-90

[77] Das A,Mennillo L.Automated surgical skill assessment in endoscopic pituitary surgery using real-time instrument tracking on a high-fidelity bench-top phantom.Healthc Technol Lett2024;11:336-344

[78] Das A,Psychogyios D.PitVis-2023 challenge: workflow recognition in videos of endoscopic pituitary surgery.Med Image Anal2025;106;103716

[79] Mao Z,Islam M.PitSurgRT: real-time localization of critical anatomical structures in endoscopic pituitary surgery.Int J Comput Assist Radiol Surg2024;19:1053-60 PMCID:PMC11178578

[80] Mamelak AN,Bruyette D.Transsphenoidal surgery using a high definition video telescope for pituitary adenomas in dogs with pituitary dependent hypercortisolism: methods and results.Vet Surg2014;43:369-79

[81] Van Stee LL,Galac S.Challenges of transsphenoidal pituitary surgery in severe brachycephalic dogs.Front Vet Sci2023;10:1154617 PMCID:PMC10318542

[82] Hanson JM,Voorhout G,Kooistra HS.Prognostic factors for outcome after transsphenoidal hypophysectomy in dogs with pituitary-dependent hyperadrenocorticism.J Neurosurg2007;107:830-40

[83] Lehner L,Csöndes J.Endoscope-guided transsphenoidal removal of a hypophyseal tumour in a dog. Case study.Magyar Állatorvosok Lapja2018;140:535-50.Available from: https://univet.hu/wp-content/uploads/2018/12/MAL-2018-09_content.pdf [Last accessed on 2 Jun 2026]

[84] Escauriaza L,Mccue J.A 3-dimensional printed patient-specific surgical guide to facilitate transsphenoidal hypophysectomy in dogs.Front Vet Sci2022;9:930856 PMCID:PMC9251581

[85] Roh Y,Jeong S.Evaluation of the accuracy of three-dimensionally printed patient-specific guides for transsphenoidal hypophysectomy in small-breed dogs.Am J Vet Res2022;83:465-72

[86] Santos ERDS,Gonçalves PE,Lyra CAM.Precision in neuronavigation systems: a systematic review and meta-analysis.Arq Bras Neurocir2024;43:e325-36

[87] Owen TJ,Frey S,Kalebaugh T.Transsphenoidal surgery: accuracy of an image-guided neuronavigation system to approach the pituitary fossa (sella turcica).Vet Surg2018;47:664-71

[88] Van Rijn S,Tryfonidou M.The influence of pituitary size on outcome after transsphenoidal hypophysectomy in a large cohort of dogs with pituitary-dependent hypercortisolism.J Vet Intern Med2016;30:989-95 PMCID:PMC5108476

[89] Guignat L.Long-term follow-up and predictors of recurrence of Cushing's disease.J Neuroendocrinol2022;34:e13186

[90] Balomenaki M,Tsagarakis S.Cushing’s disease: risk of recurrence following trans-sphenoidal surgery, timing and methods for evaluation.Pituitary2022;25:718-21

[91] Giustina A,Beckers A.Multidisciplinary management of acromegaly: a consensus.Rev Endocr Metab Disord2020;21:667-78

[92] Law HA,Short TG.Pituitary surgery in New Zealand: a single neurosurgeon case series of 1,224 operations.J Clin Neurosci2025;138:111388

[93] Fleseriu M,Freda PU.A pituitary society update to acromegaly management guidelines.Pituitary2020;24:1-13 PMCID:PMC7864830

[94] Fenn J,Scudder CJ.Efficacy of hypophysectomy for the treatment of hypersomatotropism-induced diabetes mellitus in 68 cats.J Vet Intern Med2021;35:823-33 PMCID:PMC7995378

[95] Van Bokhorst KL,Kooistra HS.Evaluation of hypophysectomy for treatment of hypersomatotropism in 25 cats.J Vet Intern Med2021;35:834-42 PMCID:PMC7995432

[96] Janelle F,Tran T.Challenges and opportunities for new intraoperative optical techniques in the surgical treatment of pituitary adenomas: a review.J Biomed Opt2025;30:080901 PMCID:PMC12344518

[97] Khan DZ,Das A.Artificial intelligence assisted operative anatomy recognition in endoscopic pituitary surgery.NPJ Digit Med2024;7:314 PMCID:PMC11550325

[98] Paul R,Kiuru A.Imaging of canine cancers with 18F-2-fluoro-2-deoxy-D-glucose (FDG) suggests further applications for cancer imaging in man.Nucl Med Commun1984;5:641-6

[99] Son Y,Kang J.High-resolution fluorodeoxyglucose positron emission tomography and magnetic resonance imaging findings of a pituitary microtumor in a dog.Ir Vet J2015;68:22 PMCID:PMC4581074

[100] Hansen AE,Engelholm SA,Kristensen AT.FDG PET/CT imaging in canine cancer patients.Vet Radiol Ultrasound2010;52:201-6

[101] Yun T,Kim S.Characteristics of ¹⁸F-FDG and ¹⁸F-FDOPA PET in an 8-year-old neutered male Yorkshire Terrier dog with glioma: long-term chemotherapy using hydroxyurea plus imatinib with prednisolone and immunoreactivity for PDGFR-β and LAT1.Vet Q2021;41:163-71 PMCID:PMC8118437

[102] Zhang J,Kang Y,Liu X.The application of augmented reality technology in endoscopic pituitary adenoma surgery via nasal approach.Gland Surg2025;14:1318-35 PMCID:PMC12322755

[103] Gieger TL,Walz J,Nolan MW.Outcomes of stereotactic radiation therapy versus fractionated radiation therapy in 44 dogs with pituitary masses: a multi-institutional retrospective study (2016-2022).Vet Comp Oncol2024;22:429-36

[104] Mondal SB,Bishop K,Margenthaler JA.Repurposing molecular imaging and sensing for cancer image-guided surgery.J Nucl Med2020;61:1113-22 PMCID:PMC7413229

[105] Litvack ZN,Laws ER.Indocyanine green fluorescence endoscopy for visual differentiation of pituitary tumor from surrounding structures: Clinical article.J Neurosurg2012;116:935-41

[106] Olesrud I,Storaker MA,Dahlberg D.Indocyanine green fluorescence in endoscopic transsphenoidal resection of pituitary neuroendocrine tumors: a systematic review.Acta Neurochir2025;167:92 PMCID:PMC11953215

[107] Vergeer RA,Van Elk T.Fluorescence-guided detection of pituitary neuroendocrine tumor (PitNET) tissue during endoscopic transsphenoidal surgery available agents, their potential, and technical aspects.Rev Endocr Metab Disord2022;23:647-57 PMCID:PMC9156450

[108] Staartjes VE,Stumpo V,Regli L.Impact of intraoperative magnetic resonance imaging on gross total resection, extent of resection, and residual tumor volume in pituitary surgery: systematic review and meta-analysis.Pituitary2021;24:644-56 PMCID:PMC8270798

[109] Wilkie N,Creighton C,Muirhead T.Mixed reality for veterinary medicine: case study of a canine femoral nerve block. In: 2020 42nd Annual International Conference of the IEEE Engineering in Medicine & Biology Society (EMBC); 2020 Jul 20-24; Montreal, QC, Canada; pp. 6074-7.

[110] Aghapour M.State of the art and future prospects of virtual and augmented reality in veterinary medicine: a systematic review.Animals2022;12:3517 PMCID:PMC9774422

[111] Li C,Yuan Y.Augmented reality navigation-guided pulmonary nodule localization in a canine model.Transl Lung Cancer Res2021;10:4152-60 PMCID:PMC8674612

[112] Shimada M,Tsujii T.Prototype of an augmented reality system to support animal surgery using HoloLens 2. In: 2022 IEEE 4th Global Conference on Life Sciences and Technologies (LifeTech); 2022 Mar 7-9; Osaka, Japan; pp. 335-7.

[113] Zhou C,Shi Y.Robot-assisted surgery for mandibular angle split osteotomy using augmented reality: preliminary results on clinical animal experiment.Aesthetic Plast Surg2017;41:1228-36

[114] Hunt JA,Anderson SL.Does virtual reality training improve veterinary students’ first canine surgical performance?.Vet Rec2020;186:562

[115] Ioannou I,Stern L.Comparison of oral surgery task performance in a virtual reality surgical simulator and an animal model using objective measures. In: 2015 37th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC); 2015 Aug 25-29; Milan, Italy; pp. 5114-7.

[116] Baskaran V,Štrkalj M.Current applications and future perspectives of the use of 3D printing in anatomical training and neurosurgery.Front Neuroanat2016;10:69 PMCID:PMC4919320

[117] Riutort KT,Damon A,Clendenen SR.Construction of an affordable lumbar neuraxial block model using 3D printed materials.Cureus2019;11:e6033 PMCID:PMC6886648

[118] Pearce P,Wijesekera A.Properties and implementation of 3-dimensionally printed models in spine surgery: a mixed-methods review with meta-analysis.World Neurosur2023;169:57-72

[119] Vakharia VN,Hill CS.Review of 3-dimensional printing on cranial neurosurgery simulation training.World Neurosur2016;88:188-98

[120] Khan DZ,Koh CH.Video-based performance analysis in pituitary surgery - part 2: artificial intelligence assisted surgical coaching.World Neurosur2024;190:e797-808

[121] Huang J,Khan DZ.Surgical AI copilot: energy-based fourier gradient low-rank adaptation for surgical LLM agent reasoning and planning.arXiv2025;arXiv:2503.09474.

[122] Iqbal MJ,Sadia H.Clinical applications of artificial intelligence and machine learning in cancer diagnosis: looking into the future.Cancer Cell Int2021;21:270 PMCID:PMC8139146

[123] Jones OT,Van Der Schaar M.Artificial intelligence and machine learning algorithms for early detection of skin cancer in community and primary care settings: a systematic review.Lancet Digit Health2022;4:e466-76

[124] Liu J,Ou Y.Mammography diagnosis of breast cancer screening through machine learning: a systematic review and meta-analysis.Clin Exp Med2022;23:2341-56

[125] Kent MS.Updates on radiation therapy for pituitary tumors.Vet Clin N Am Anim Pract2025;55:119-33

[126] Kent MS,Feldman E.Survival, neurologic response, and prognostic factors in dogs with pituitary masses treated with radiation therapy and untreated dogs.J Vet Intern Med2007;21:1027-33

[127] Brearley MJ,Littler RM.Coarse fractionated radiation therapy for pituitary tumours in cats: a retrospective study of 12 cases.Vet Comp Oncol2006;4:209-17

[128] de Fornel P, Delisle F, Devauchelle P, Rosenberg D. Effects of radiotherapy on pituitary corticotroph macrotumors in dogs: a retrospective study of 12 cases.Can Vet J2007;48:481-6 PMCID:PMC1852601

[129] Rapastella S,Sharman M.Effect of pituitary-dependent hypercortisolism on the survival of dogs treated with radiotherapy for pituitary macroadenomas.J Vet Intern Med2023;37:1331-40 PMCID:PMC10365051

[130] Hansen KS,Théon AP.Long-term survival with stereotactic radiotherapy for imaging-diagnosed pituitary tumors in dogs.Vet Radiol Ultrasound2018;60:219-32

[131] Marcinowska A,Brearley M.Comparison of two coarse fractionated radiation protocols for the management of canine pituitary macrotumor: an observational study of 24 dogs.Vet Radiol Ultrasound2015;56:554-62

[132] Kaser-Hotz B,Stankeova S,Fidel J.Radiotherapy of pituitary tumours in five cats.J Small Anim Pract2002;43:303-7

[133] Körner M,Meier VS.Radiation therapy for intracranial tumours in cats with neurological signs.J Feline Med Surg2018;21:765-71 PMCID:PMC10814305

[134] Mayer MN,LaRue SM.Outcomes of pituitary tumor irradiation in cats.J Vet Intern Med2006;20:1151-4.

[135] Sellon R,Houston R.Linear-accelerator-based modified radiosurgical treatment of pituitary tumors in cats: 11 cases (1997-2008).J Vet Intern Med2009;23:1038-44

[136] Sawada H,Lee P,Oda H.Pituitary size alteration and adverse effects of radiation therapy performed in 9 dogs with pituitary-dependent hypercortisolism.Res Vet Sci2018;118:19-26

[137] Goossens MMC,Theon AP.Efficacy of cobalt 60 radiotherapy in dogs with pituitary-dependent hyperadrenocorticism.J Am Vet Med Assoc1998;212:374-6

[138] Théon AP.Megavoltage irradiation of pituitary macrotumors in dogs with neurologic signs.J Am Vet Med Assoc1998;213:225-31

[139] Wormhoudt TL,Lunn K.Stereotactic radiation therapy for the treatment of functional pituitary adenomas associated with feline acromegaly.J Vet Intern Med2018;32:1383-91 PMCID:PMC6060317

[140] Bley CR,Roos M.Irradiation of brain tumors in dogs with neurologic disease.J Vet Intern Med2005;19:849-54.

[141] Gieger TL.Treatment outcomes and target delineation utilizing CT and MRI in 13 dogs treated with a uniform stereotactic radiation therapy protocol (16 Gy single fraction) for pituitary masses: (2014-2017).Vet Comp Oncol2020;19:17-24

[142] Mariani CL,House RA.Frameless stereotactic radiosurgery for the treatment of primary intracranial tumours in dogs.Vet Comp Oncol2013;13:409-23

[143] Park P,Barkan AL.The role of radiation therapy after surgical resection of nonfunctional pituitary macroadenomas.Neurosur2004;55:100-7

[144] Green S,Cifarelli CP.Congress of neurological surgeons systematic review and evidence-based guidelines for the role of radiosurgery for patients with functioning pituitary adenomas.Neurosurgery2025;97:S36-43

[145] Minniti G.The risk/benefit ratio of radiotherapy in pituitary tumors.Best Pract Res Clin Endocrinol Metab2019;33:101269

[146] Morsink NC,Meij BP.Case report: radioactive holmium-166 microspheres for the intratumoral treatment of a canine pituitary tumor.Front Vet Sci2021;8:748247 PMCID:PMC8600255

[147] Besser G.Cushing's syndrome.Clin Endocrinol Metab1972;1:451-90

[148] Kelsall A.Cushing's disease-from Minnie G to key issues in the early 21st century.Lancet Diabetes Endocrinol2019;7:959-64

[149] Luton JP,Bouchard P.Treatment of Cushing's disease by o,p′DDD: survey of 62 cases.N Engl J Med1979;300:459-64

[150] Carmichael JD.Mifepristone: is there a place in the treatment of Cushing’s disease?.Endocrine2012;44:20-32

[151] Schofield I,Wilson ARL.Survival analysis of 219 dogs with hyperadrenocorticism attending primary care practice in England.Vet Rec2020;186:333-60 PMCID:PMC7146928

[152] Patel J,Liu JK.Nelson's syndrome: a review of the clinical manifestations, pathophysiology, and treatment strategies.Neurosurg Focus2015;38:E14

[153] Teshima T,Takekoshi S.Trilostane-induced inhibition of cortisol secretion results in reduced negative feedback at the hypothalamic–pituitary axis.Domest Anim Endocrinol2009;36:32-44

[154] Fracassi F,Floriano D.Prognostic factors for survival in dogs with pituitary-dependent hypercortisolism treated with trilostane.Vet Rec2015;176:49

[155] Galac S,Mol JA.Effects of trilostane on the pituitary-adrenocortical and renin–aldosterone axis in dogs with pituitary-dependent hypercortisolism.Vet J2010;183:75-80

[156] García San José P,Alonso-Miguel D.Survival of dogs with pituitary-dependent hyperadrenocorticism treated twice daily with low doses of trilostane.Vet Rec2022;191:e1630

[157] Nagata N,Yuki M.Comparison of survival times for dogs with pituitary-dependent hyperadrenocorticism in a primary-care hospital: treated with trilostane versus untreated.J Vet Intern Med2017;31:22-8 PMCID:PMC5259634

[158] De Bruin C,Meij BP.Expression and functional analysis of dopamine receptor subtype 2 and somatostatin receptor subtypes in canine cushing’s disease.Endocrinology2008;149:4357-66 PMCID:PMC2553383

[159] Castillo V,Lalia J,García J.Cushing’s disease in dogs: cabergoline treatment.Res Vet Sci2008;85:26-34

[160] Scudder CJ,Gostelow R.Pilot study assessing the use of cabergoline for the treatment of cats with hypersomatotropism and diabetes mellitus.J Feline Med Surg2020;23:131-7 PMCID:PMC10741349

[161] Miceli DD,Pompili GA.Cabergoline treatment in cats with diabetes mellitus and hypersomatotropism.J Feline Med Surg2022;24:1238-44 PMCID:PMC10812327

[162] Golinelli S,Pöppl AG.Addition of cabergoline to trilostane treatment for dogs with pituitary-dependent hypercortisolism.J Vet Intern Med2024;38:1-864Available from: https://cris.unibo.it/handle/11585/955590 [Last accessed on 12 Jun 2026]

[163] Weckbecker G,Lewis I.SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs.Endocrinology2002;143:4123-30

[164] Castillo V,Stalla J.Effect of SOM230 (Pasireotide) on corticotropic cells: action in dogs with Cushing’S disease.Neuroendocrinology2011;94:124-36

[165] Lottati M.Outcomes of the addition of pasireotide to traditional adrenal-directed treatment for dogs with pituitary-dependent hyperadrenocorticism secondary to macroadenoma: 9 cases (2013-2015).J Am Vet Med Assoc2018;252:1403-8

[166] Jaquet P,Saveanu A.Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy.Eur J Endocrinol2005;153:135-41

[167] Castillo V,Páez-Pereda M.Retinoic acid as a novel medical therapy for Cushing’S disease in dogs.Endocrinology2006;147:4438-44

[168] Occhi G,Albiger NM.Activation of the dopamine receptor type-2 (DRD2) promoter by 9-cis retinoic acid in a cellular model of Cushing's disease mediates the inhibition of cell proliferation and ACTH secretion without a complete corticotroph-to-melanotroph transdifferentiation.Endocrinology2014;155:3538-49

[169] Vilar L,Lyra R.The role of isotretinoin therapy for Cushing’s disease: results of a prospective study.Int J Endocrinol2016;2016:1-9 PMCID:PMC4789464

[170] Young RB,Sweat ML.Complexing of DDT and o,p'DDD with adrenal cytochrome P-450 hydroxylating systems.J Steroid Biochem1973;4:585-91

[171] Kroiss M,Lutz WK,Fassnacht M.Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma.Clin Endocrinol2011;75:585-91

[172] Sbiera S,Liebisch G.Mitotane inhibits sterol-o-Acyl transferase 1 triggering lipid-mediated endoplasmic reticulum stress and apoptosis in adrenocortical carcinoma cells.Endocrinology2015;156:3895-908

[173] King J.Incidence and risk factors for hypoadrenocorticism in dogs treated with trilostane.Vet J2017;230:24-9

[174] Fleseriu M.Updates on the role of adrenal steroidogenesis inhibitors in Cushing’s syndrome: a focus on novel therapies.Pituitary2016;19:643-53 PMCID:PMC5080363

[175] Daniel E,Mustafa O.Effectiveness of metyrapone in treating Cushing's syndrome: a retrospective multicenter study in 195 patients.J Clin Endocrinol Metab2015;100:4146-54 PMCID:PMC5393433

[176] Newell-Price J,Pivonello R.Improved clinical outcomes during long-term osilodrostat treatment of cushing disease with normalization of late-night salivary cortisol and urinary free cortisol.J Endocr Soc2025;9:bvae201 PMCID:PMC11604051

[177] Feelders RA,De Herder WW.Medical treatment of cushing’s syndrome: adrenal-blocking drugs and ketaconazole.Neuroendocrinology2010;92:111-5

[178] Muthukuda DT,Jayawickreme KP.Etomidate in severe cushing syndrome: a systematic review.J Endocr Soc2025;9:bvaf039 PMCID:PMC11920866

[179] Mountjoy KG,Mortrud MT.The cloning of a family of genes that encode the melanocortin receptors.Science1992;257:1248-51

[180] Sanders K,Kooistra HS.Melanocortin 2 receptor antagonists in canine pituitary-dependent hypercortisolism: in vitro studies.Vet Res Commun2018;42:283-8 PMCID:PMC6244543

[181] Schimmer BP.Minireview: steroidogenic factor 1: its roles in differentiation, development, and disease.Mol Endocrinol2010;24:1322-37 PMCID:PMC5417463

[182] Sanders K,Slob A,Galac S.Steroidogenic factor-1 inverse agonists as a treatment option for canine hypercortisolism: in vitro study.Domest Anim Endocrinol2018;63:23-30

[183] Brown DR,Eilerman BS.Clinical management of patients with Cushing syndrome treated with mifepristone: consensus recommendations.Clin Diabetes Endocrinol2020;6:18 PMCID:PMC7596972

[184] Molitch ME.Glucocorticoid receptor blockers.Pituitary2022;25:733-6

[185] Castinetti F,Johanssen S.Merits and pitfalls of mifepristone in Cushing's syndrome.Eur J Endocrinol2009;160:1003-10

[186] Van Stee L. The growth inhibitory effect of of anti growth hormone (G144K) on canine mammary carcinomasDSpace/Manakin Repository. Available from: https://research-portal.uu.nl/en/publications/the-growth-inhibitory-effect-of-of-anti-growth-hormone-g144k-on-c/ [Last accessed on 12 Jun 2026]

[187] Lien Y.Use of ketoconazole to treat dogs with pituitary-dependent hyperadrenocorticism: 48 cases (1994-2007).J Am Vet Med Assoc2008;233:1896-901

[188] Slingerland L,Rijnberk A.Growth hormone excess and the effect of octreotide in cats with diabetes mellitus.Domest Anim Endocrinol2008;35:352-61

[189] Scudder CJ,Forcada Y,Church D.Pasireotide for the medical management of feline hypersomatotropism.J Vet Intern Med2015;29:1074-80

[190] Gostelow R,Keyte S.Pasireotide long-acting release treatment for diabetic cats with underlying hypersomatotropism.J Vet Intern Med2017;31:355-64 PMCID:PMC5354018

[191] Ay SS,Önyay F.Effect of oral misoprostol, alone or in combination with aglepristone, on mid-term pregnancy termination in cats.J Feline Med Surg2018;21:714-22 PMCID:PMC10814293

[192] Concannon PW,Frank D.Termination of pregnancy and induction of premature luteolysis by the antiprogestagen, mifepristone, in dogs.Reproduction1990;88:99-104

[193] Dijkstra KK,Weeber F.Patient-derived organoid models of human neuroendocrine carcinoma.Front Endocrinol2021;12:627819 PMCID:PMC7991829

[194] Van Den Berg MF MF,Viets FC.Canine adrenomedullary and pheochromocytoma organoids: a novel in vitro model.Endocrinology2025;166:bqaf114 PMCID:PMC12264429

[195] Ginai M,Hewitt CJ,Fenner K.The use of bioreactors as in vitro models in pharmaceutical research.Drug Discov Today2013;18:922-35

[196] Bovard D,Luettich K,Peitsch MC.Organs-on-a-chip: a new paradigm for toxicological assessment and preclinical drug development.Toxicol Res Appl2017;1:2397847317726351